[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aorto-iliac-occlusive-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aorto-iliac-occlusive-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100598368","impact-of-aorto-iliac-occlusive-disease-treatment-on-blood-pressure-100598368",false,"NCT07070583","Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure","Impact of Endovascular Treatment of Aorto-iliac Disease on Systemic Hypertension A Pilot Study Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure","Inclusion Criteria:\n\n* Age ≥18 years\n* Singed informed consent\n* Chronic occlusion in the infrarenal aorta and\u002For one or both common iliac arteries\n* Total lesion length of ≥30mm\n* Clinical indication for treatment of the pathology (Chronic limb threatening ischemia or disabling intermittent claudication not responding to supervised exercise training)\n\nExclusion Criteria:\n\n* Patient is unable to understand the study requirements and\u002F or is unwilling to adhere to the follow-up\n* Juxtarenal pathology (\\\u003C2cm below the lowest renal artery)\n* Acute occlusion of the target area (Acute Leriche Syndrome)\n* Embolic disease","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Hypertension is a major risk factor for a variety of cardiovascular diseases. When hypertension results from increased vascular resistance due to a narrowing of the descending aorta, it can be effectively treated with stenting. More recently, evidence suggest that stenting in more distal parts of the arterial vascular bed is also associated with a reduction in blood pressure. The investigators hypothesize that stenting of occlusions more distal of the descending aorta decreases the central blood pressure and afterload as reflected by NT-proBNP (N-terminal pro-Brain Natriuretic Peptide), a biomarker of intracardiac pressures and predictor of heart failure events. The goal of this pilot study is to prospectively investigate changes in blood pressure after stent placement in the aorto-iliac region.",[26,27],"Aorto Iliac Occlusive Disease","Blood Pressure","RECRUITING","2026-03-30",{"date":31,"type":32},"2026-04-03","ACTUAL",{"date":29,"type":32},{"date":35,"type":20},"2027-12-31",{"name":37,"class":38},"Rijnstate Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100501119","prospective-non-randomised-clinical-trial-to-investigate-the-begraft-aortic-stent-graft-system-and-the-begraft-peripheral-stent-graft-system-treating-aortic-iliac-occlusive-disease-100501119","NCT05805111","Prospective, Non-Randomised Clinical Trial to Investigate the BeGraft Aortic Stent Graft System and the BeGraft Peripheral Stent Graft System Treating Aortic-iliac Occlusive Disease","CERAB - Prospective, Non-Randomised Clinical Trial to Investigate the BeGraft Aortic Stent Graft System and the BeGraft Peripheral Stent Graft System Treating Aortic-iliac Occlusive Disease With CERAB","General Inclusion criteria\n\n1. Patient has been identified with an chronic aorto-iliac occlusive lesion, with clinical necessity for treatment.\n2. The patient has been diagnosed with symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 2 to 5.\n3. Patient has a projected life-expectancy of at least 24 months.\n4. Patient is ≥18 years old.\n5. Patient is willing\u002Fcapable and provides written consent to participate to the trial and confirmed to attend the expected follow-up visits.\n\nAngiographic inclusion criteria:\n\n1. Patient's anatomy is eligible for CERAB treatment, without the need for chimneys and can be treated with a Ø 12 mm BGA.\n2. The aorto-iliac lesion begins at least 1 cm below the patent renal arteries without a need for treatment.\n3. A maximum of 3 BeGraft Peripheral (Ø 7 or 8 mm) per limb in the iliac artery can be used. In case a Ø 7 mm is used to extend, the overlapping end must be post-dilated to ensure proper flow.\n4. The target lesion has angiographic evidence of stenosis \\>50% or occlusion.\n5. Patient's common femoral artery and deep femoral artery are patent.\n\nGeneral Exclusion criteria:\n\n1. Patient is currently participating in another interventional drug trial or device trial that has not completed the entire follow up period.\n2. Patient has planned any surgical intervention\u002Fprocedure, that is not related to the study procedure, within 30 days after the study procedure.\n3. Patient had a Myocardial infarction or stroke within a period of 3 months prior to the study procedure.\n4. Patient had surgery (e.g. bypass surgery or stenting) in target vessels previously.\n5. Patient has an acute severe systemic infection at time of screening or in period of 30 days prior to screening.\n6. Patient has fresh thrombus at time of screening or in period of 14 days prior to screening.\n7. Patient has a CERAB procedure that is staged.\n8. Female patient with childbearing potential not taking adequate contraceptives.\n9. Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated.\n10. Patients with known hypersensitivity to the stent material (L605) and\u002For PTFE.\n11. Patients who are placed in an institution due to an institutional or court order.\n12. An aneurysm in the abdominal aortic and iliac segments where CERAB will be placed is present.\n13. Patient has or had aortic coarctation.\n14. Patient had aortic injury\u002Ftrauma related interventions previously.\n15. Patient had suprarenal\u002Fvisceral segment reconstructions previously.\n\nAngiographic exclusion criteria\n\n1. Failure of recanalization\n2. A relevant accessory renal artery (\\>3 mm) in the infrarenal aorta is present, that might be occluded during the procedure.","99 Years",{"count":49,"type":20},109,"OBSERVATIONAL","This is a prospective, multi-center, investigational study to evaluate safety and performance of the BeGraft Aortic balloon expandable covered Stent Graft System and the BeGraft Peripheral balloon expandable covered stent Graft System (Bentley InnoMed GmbH, Hechingen, Germany) implanted as covered stents in CERAB procedures (Covered Endovascular Reconstruction of Aortic Bifurcation) for extensive aorto-iliac occlusive disease.\n\nThe objective of this clinical investigation is to evaluate the safety and performance of the BeGraft Aortic covered stent Graft System \\& the BeGraft Peripheral covered stent Graft System (Bentley Innomed, Hechingen, Germany) in CERAB configuration (Covered Endovascular Reconstruction of Aortic Bifurcation) for Aorto-iliac Occlusive Disease.",[53],"Aorto-iliac Occlusive Disease","2025-06-11",{"date":56,"type":32},"2025-06-15",{"date":58,"type":32},"2024-04-05",{"date":60,"type":20},"2027-07",{"name":62,"class":38},"Marc Bosiers, MD",15]